Contemporary outcomes of debridement, antibiotics and implant retention in knee arthroplasty
- PMID: 38529130
- PMCID: PMC10929323
- DOI: 10.21037/aoj-20-76
Contemporary outcomes of debridement, antibiotics and implant retention in knee arthroplasty
Abstract
Periprosthetic joint infection (PJI) is a major complication after knee arthroplasty, with approximately a quarter of knee arthroplasty revisions citing PJI as an indication. With the demand for knee arthroplasty predicted to increase, coupled with a lack of evidence for decreasing PJI risk, an appreciation of the burdens of PJI on both patients and health care systems is vital. Patients with PJI can experience a reduced quality of life as well as increased morbidity, whilst the management of PJI has significant economic implications. Surgical options include debridement, antibiotics and implant retention (DAIR), single-stage revision, two-stage revision and salvage procedures. DAIR involves the systematic debridement of all infected and unhealthy tissues coupled with directed antibiotic therapy, with definitive infection clearance the objective. In contrast to single- and two-stage revision procedures for PJI, DAIR does not involve the removal of fixed implants, with only modular components exchanged. Potential benefits of DAIR include reduced tissue destruction, reduced morbidity and reduced healthcare burdens, but with a higher reinfection risk compared to staged revision techniques, and utility largely restricted to acute bacterial PJI. A review of contemporary DAIR outcomes is of value given advances in the understanding of PJI biology; the development of consensus-based definitions for PJI diagnosis and treatment outcomes; and evolution of DAIR indications and technique. This review discusses outcomes of DAIR for knee PJI, published over the last two decades.
Keywords: Knee; antibiotics and implant retention; arthroplasty; debridement; debridement, antibiotics and implant retention (DAIR); infection; periprosthetic joint infection (PJI).
2022 Annals of Joint. All rights reserved.
Conflict of interest statement
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/aoj-20-76). The series “Prosthetic Joint Infection” was commissioned by the editorial office without any funding or sponsorship. AP serves as an unpaid editorial board member of Annals of Joint from July 2019 to June 2021. The authors have no other conflicts of interest to declare.
Similar articles
-
The Double DAIR: A 2-Stage Debridement with Prosthesis-Retention Protocol for Acute Periprosthetic Joint Infections.JBJS Essent Surg Tech. 2021 Feb 4;11(1):e19.00071-e19.00071. doi: 10.2106/JBJS.ST.19.00071. eCollection 2021 Jan-Mar. JBJS Essent Surg Tech. 2021. PMID: 34123550 Free PMC article.
-
Failed Debridement and Implant Retention Does Not Compromise the Success of Subsequent Staged Revision in Infected Total Knee Arthroplasty.J Arthroplasty. 2019 Jun;34(6):1214-1220.e1. doi: 10.1016/j.arth.2019.01.066. Epub 2019 Feb 2. J Arthroplasty. 2019. PMID: 30826164
-
Debridement, antibiotics, and implant retention after revision arthroplasty : antibiotic mismatch, timing, and repeated DAIR associated with poor outcome.Bone Joint J. 2022 Apr;104-B(4):464-471. doi: 10.1302/0301-620X.104B4.BJJ-2021-1264.R1. Bone Joint J. 2022. PMID: 35360944 Review.
-
Outcome of Debridement, Antibiotics, and Implant Retention With Modular Component Exchange in Acute Culture-Negative Periprosthetic Joint Infections.J Arthroplasty. 2021 Mar;36(3):1087-1093. doi: 10.1016/j.arth.2020.08.065. Epub 2020 Sep 7. J Arthroplasty. 2021. PMID: 32981773
-
A guide to debridement, antibiotics, and implant retention.Ann Jt. 2022 Jan 15;7:5. doi: 10.21037/aoj-20-89. eCollection 2022. Ann Jt. 2022. PMID: 38529146 Free PMC article. Review.
Cited by
-
One-year success after debridement, antibiotic therapy, and implant retention for acute hip and knee periprosthetic joint infection: a retrospective cohort study of 62 patients.Eur J Orthop Surg Traumatol. 2025 Jul 22;35(1):316. doi: 10.1007/s00590-025-04438-7. Eur J Orthop Surg Traumatol. 2025. PMID: 40696238
-
Oritavancin a Therapeutic Option for Periprosthetic Joint Infections in Selected Cases: A Comprehensive Review.Pharmaceuticals (Basel). 2025 Aug 18;18(8):1217. doi: 10.3390/ph18081217. Pharmaceuticals (Basel). 2025. PMID: 40872608 Free PMC article. Review.
References
Publication types
LinkOut - more resources
Full Text Sources